BJMO - 2024, issue 3, may 2024
E. Landeloos MD
Immune checkpoint inhibitors have become the standard of care in previously untreated melanoma, reaching a median overall survival exceeding three years. While particularly successful in some, a significant portion of patients will never obtain treatment benefit. Over a decade of research has revealed a complex and dynamic interaction between a myriad of cancer-intrinsic and -extrinsic factors driving immune evasion, which emerge during tumour formation and shift early during treatment. In this review, we discuss primary resistance mechanisms to immune checkpoint inhibition in melanoma, and consider predictive biomarkers and their potential clinical implications.
(BELG J MED ONCOL 2024;18(3):75–81
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
